Denosumab discontinuation in non-metastatic breast cancer treated with AI raises vertebral fracture risk

Aromatase inhibitors (AIs) are a cornerstone of adjuvant therapy for hormone receptor–positive breast cancer, significantly reducing recurrence and mortality. However, by suppressing estrogen production, AIs accelerate bone loss and increase fracture risk. To counter this, antiresorptive therapies such as denosumab or bisphosphonates are widely recommended.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup